PGN Conference Centre
431 50 Mölndal
Discounted Accommodation for Cell Based Assay 2022 can be booked at the Quality Hotel the Weaver
431 37 Mölndal
Double room for single use ink breakfast and VAT (free Wi-Fi) SEK 950:- Please book your room via the link
ELRIG´s Advances in Cell Based Profiling in Drug Discovery 2022
The fourth ELRIG meeting on Advances in Cell Based Profiling in Drug Discovery will be held on May 10-12 at the AstraZeneca R&D site in Gothenburg. This interactive 3-day event will host leading scientists from academia, industry and the vendor community to discuss current and future formats for cell based assays. Building on the success from last time, the third day of the meeting is organized by key academic chemical biology infrastructures in the Nordic countries. Our ambition is to create an open and inspiring environment for networking between biologists and chemists, discussing the latest advancements and best practices in cell assay profiling and their application for target identification, target validation and compound optimisation purposes.
Cell based assays are utilized at all stages of drug discovery to explore disease mechanisms and to identify novel molecular therapeutics. To achieve this the field is continuously looking for improvements in cell reagents, assay formats, and readouts to ensure disease-relevant contexts, aiming at improving translation to human physiology. Implementation of cell assays with improved translatability is much needed for improving success rates in drug discovery, but we are struggling with restrictions in cell availability and assay costs, considerations that are holding back their broader implementation. This meeting will explore these challenges and look into how cell profiling efforts must be adapted to emerging drug modalities, in this case with a special focus on therapeutic oligonucleotides and other modalities that affect protein levels rather than their activities.
The meeting program is developed around five key focus areas:
Enabling Advanced Cell Models in Profiling
This session explores how to embrace individual diversity and variability in drug discovery through the use of advanced cell models. Topics will flow from the relevance of diverse genetic backgrounds in generating disease models, through advances in long-term provision of these cells and possibilities for miniaturisation, to the use of multiparametric and multidimensional readouts for better biological interpretation of data.
Towards a complete temporal and spatial understanding of cellular responses
Positive demonstration of target engagement and translation to expected biomarkers of treatment response are known to correlate with successful progression of clinical studies. Here we explore case studies that looks broadly at treatment response – from interaction with intended molecular target to a map of disease-relevant cell responses – and the potential heterogeneity of such responses between cell models.
Designing cell profiling support for therapeutic OLIGO discovery
Seasoned drug discoverers are well versed when it comes to designing panels of assays for optimization of small molecule-based drugs and therapeutic antibodies. With the entrance of new clinically validated drug modalities, such as antisense oligonucleotides, these screening cascades must be re-built to suit the needs. This session is dedicated to sharing successful examples of cell profiling performed in the field of therapeutic oligonucleotides.
The rise of high throughput protein MS in cellular profiling
Moder n drug modalities such as antisense oligonucleotides and PROTACs function by removing target proteins of interest, adding significantly to the repertoire of tools available for disease modulation. Complementing antibody-based approaches for assessing impact on endogenous protein levels, this session will explore recent advances in high throughput applications of protein mass spectrometry.
Using Biology for Fingerprinting Compounds (Nordic Chemical Biology infrastructures)
Small molecule profiling or “drug fingerprinting” is defined by systematic testing of well-characterized chemical libraries across disease models to uncover biological mechanisms fundamental to health and disease. This session will explore this interesting interplay between chemistry and biology and includes talks on functional fragments as well as image-based fingerprinting using high-content imaging.
There will be ample opportunity for networking with scientists and researchers from the pharmaceutical, academic and vendor communities throughout the 3- day conference. The program also includes poster viewing sessions, poster snapshot presentation opportunities for select high quality posters and a tour of the Amazing Journey at AstraZeneca.
It is a great pleasure for us to welcome you to Gothenburg for an exciting three days in May of 2022!
Per-Erik Strömstedt, Thomas Lundbäck, Karin Angelin Krefting, Sam Barichievy, James Robinson, and Helena Lindmark (AstraZeneca)
Anna-Lena Gustavsson (Karolinska Institutet)
Bagmi Pattanaik (University of Gothenburg)
Benedikt von der Heyde (Pelago Bioscience)
The Nordic infrastructures on Chemical Biology and Personalized Medicine
The Programme will appear here shortly
POSTER ABSTRACTS SUBMISSION IS NOW OPEN.
The final day for submitting is Sunday, May 01, 2022.
To submit an abstract, first you must Register Once completed your will be able to “Turn on Abstract Submissions” From here you can manage your abstracts.
A Poster at Cell Based Screening 2022 will be both a physical and digital poster. The physical poster should be A0 Portrait and there will be a board reserved for you in the Exhibition Room. The digital poster requires a PDF (Max 5mg) to be added to your poster at registration.
If you have already registered, you can login to your account here and “Turn on Abstract Submissions”
ALL OUR EVENT INFORMATION IN
THE PALM OF YOUR HAND
If you plan to attend an ELRIG event download the free ELRIG app and access all our conference information and lecture schedules and more straight from your phone or pad..